[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506432":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":20,"armGroups":28,"interventions":43,"overallOfficials":49,"centralContacts":57,"locations":66,"responsibleParty":98,"collaborators":100,"id":106,"slug":20,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":20,"eligibilityCriteria":111,"healthyVolunteers":107,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":20,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":20,"overallStatus":68,"whyStopped":20,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Frontera Therapeutics","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of AEs","Number and proportion of Adverse Events","from FT-002 administration through up to 1 years",[14,17],{"measure":15,"description":16,"timeFrame":12},"Change in visual function","Change in retinal function as assessed by mean retinal sensitivity within the 30-degree visual field",{"measure":18,"description":19,"timeFrame":12},"Change in retinal structure as assessed by Optical Coherence Tomography","Change in Outer Nuclear Layer Thickness from baseline as assessed by Optical Coherence Tomography",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":24,"primaryPurpose":25,"observationalModel":20,"timePerspective":20,"maskingInfo":26},"NON_RANDOMIZED","SEQUENTIAL","X-linked retinitis pigmentosa patients","TREATMENT",{"masking":27,"maskingDescription":20,"whoMasked":20},"NONE",[29,35,39],{"label":30,"type":31,"description":32,"interventionNames":33},"Low dose FT-002","EXPERIMENTAL","Intraocular injection of a single low dose of FT-002",[34],"Genetic: FT-002",{"label":36,"type":31,"description":37,"interventionNames":38},"Intermediate dose FT-002","Intraocular injection of a single Intermediate dose of FT-002",[34],{"label":40,"type":31,"description":41,"interventionNames":42},"High dose FT-002","Intraocular injection of a single High dose of FT-002",[34],[44],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":20},"GENETIC","FT-002","Comparison of different dosages of FT-002",[40,36,30],[50,54],{"name":51,"affiliation":52,"role":53},"Gezhi Xu","Eye & ENT Hospital of Fudan University","PRINCIPAL_INVESTIGATOR",{"name":55,"affiliation":56,"role":53},"Ruifang Sui","Peking Union Medical College Hospital",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":20,"email":62},"Xinyan Li","CONTACT","+86-021-58206061","xinyan.li@fronteratherapeutics.com",{"name":64,"role":60,"phone":61,"phoneExt":20,"email":65},"Minghui Xue","minghui.xue@fronteratherapeutics.com",[67,83],{"facility":56,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":75,"coordinates":76},"Point",[77,78],116.39723,39.9075,{"lat":78,"lon":77},[81],{"name":82,"role":60,"phone":20,"phoneExt":20,"email":20},"Ruifang Sui, Professor",{"facility":84,"status":68,"city":85,"state":86,"zip":87,"country":72,"countryCode":73,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Eye & ENT hospital of Fudan university","Shanghai","Shanghai Municipality","200032",{"type":75,"coordinates":89},[90,91],121.45806,31.22222,{"lat":91,"lon":90},[94,96],{"name":95,"role":60,"phone":20,"phoneExt":20,"email":20},"Gezhi Xu, Professor",{"name":97,"role":60,"phone":20,"phoneExt":20,"email":20},"Jihong Wu, Professor",{"type":99,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[101,103,104],{"name":52,"class":102},"OTHER",{"name":56,"class":102},{"name":105,"class":102},"Henan Provincial People's Hospital","100506432",false,"NCT05874310","Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa","An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.","Inclusion Criteria:\n\n1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;\n\nExclusion Criteria:\n\n1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.","MALE","8 Years","45 Years",{"count":116,"type":117},18,"ESTIMATED","INTERVENTIONAL",[120],"EARLY_PHASE1","A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).",[123],"X-Linked Retinitis Pigmentosa","2023-05-23",{"date":126,"type":127},"2023-05-24","ACTUAL",{"date":129,"type":127},"2023-02-01",{"date":131,"type":117},"2027-11-01",{"name":5,"class":6},2]